Cert Medical Oncology(SA) Phys Practice Questions - Sub-specialty Certificate In Medical Oncology Of The College Of Physicians Of South Africa Exam

Access More Questions

A 52-year-old female with metastatic HER2-positive breast cancer experiences disease progression in the liver and lungs while receiving first-line Pertuzumab, Trastuzumab, and Docetaxel. Her ECOG performance status is 1. What is the most appropriate second-line systemic treatment choice supported by the DESTINY-Breast03 phase III trial?

Lapatinib + Capecitabine Trastuzumab emtansine (T-DM1) Trastuzumab deruxtecan (T-DXd) Tucatinib + Trastuzumab + Capecitabine

Correct Answer:

Trastuzumab deruxtecan (T-DXd)

Access more questions from this quiz

Continue to Cert Medical Oncology(SA) Phys Practice Questions - Sub-specialty Certificate in Medical Oncology of the College of Physicians of South Africa Exam for more practice questions and the full quiz experience.

Access More Questions